RESULTS: The prevalence of elevated serum T-IgE and AH in patients with COPD was 47.3% and 15.0%, respectively. Eight patients (2.9%) met the diagnostic criteria for ABPA. Compared with the normal T-IgE group, patients with elevated T-IgE had a longer history of dyspnea (p<0.01), an earlier onset of dyspnea after chronic cough/expectation (p<0.01), and were more likely to wheeze (p<0.01). They also showed worse lung functions and more severe GOLD staging (p<0.01). Analysis of the clinical data in male patients with smoking as the risk factor showed the same results. To evaluate the clinical characteristics of COPD with AH, patients with elevated T-IgE were further divided into subgroups with and without AH. When compared with the normal T-IgE group, both the two subgroups showed longer history of dyspnea (p<0.01), an earlier onset of dyspnea (p<0.01) and a worse status of lung function (p<0.05). Correlation analysis demonstrated that serum T-IgE was correlated positively with the time length of dyspnea (r=0.401, p<0.001), and the ratio of duration of dyspnea to that of chronic cough/expectation (r=0.59, p<0.001), but negatively with FEV1/FVC% (r=−0.194, p=0.001), and FEV1% predicted (r=−0.219, p<0.001).